Divi's Laboratories inks manufacturing and supply agreement with global pharma company

The company expects meaningful revenue contribution from this long-term agreement

Lupin and SteinCares ink agreement for Ranibizumab in Latin America

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Biocon gets six-month extension on insulin supply pact in Malaysia

The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025

Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr

The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds

Punita Lal Joins Lupin Board as Additional Director

She has held senior positions at Coca-Cola in China and PepsiCo in India

Lupin receives USFDA approval for Rivaroxaban Tablets